Stella Pharma Income Statement

Financials in millions JPY. Fiscal year is April - March.

Millions JPY. Fiscal year is Apr - Mar.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2019 - 2020
Period Ending	Mar '25 Mar 31, 2025	Mar '24 Mar 31, 2024	Mar '23 Mar 31, 2023	Mar '22 Mar 31, 2022	Mar '21 Mar 31, 2021	2019 - 2020
Revenue	961	269	229	100	205	Upgrade
Revenue Growth (YoY)	257.25%	17.47%	129.00%	-51.22%	-	Upgrade
Cost of Revenue	116	52	22	15	24	Upgrade
Gross Profit	845	217	207	85	181	Upgrade
Selling, General & Admin	935	571	625	555	539	Upgrade
Research & Development	-	393	374	255	307	Upgrade
Operating Expenses	935	977	1,013	826	862	Upgrade
Operating Income	-90	-760	-806	-741	-681	Upgrade
Interest Expense	-4	-2	-2	-3	-3	Upgrade
Interest & Investment Income	1	1	1	-	-	Upgrade
Other Non Operating Income (Expenses)	-45	-	31	-20	27	Upgrade
Pretax Income	-138	-761	-776	-764	-657	Upgrade
Income Tax Expense	2	2	2	3	2	Upgrade
Net Income	-140	-763	-778	-767	-659	Upgrade
Net Income to Common	-140	-763	-778	-767	-659	Upgrade
Shares Outstanding (Basic)	33	31	29	28	20	Upgrade
Shares Outstanding (Diluted)	33	31	29	28	20	Upgrade
Shares Change (YoY)	7.76%	7.27%	2.83%	40.17%	28.43%	Upgrade
EPS (Basic)	-4.19	-24.63	-26.94	-27.31	-32.89	Upgrade
EPS (Diluted)	-4.19	-24.63	-26.94	-27.31	-32.89	Upgrade
Free Cash Flow	136	-886	-853	-1,127	-793	Upgrade
Free Cash Flow Per Share	4.07	-28.60	-29.54	-40.13	-39.58	Upgrade
Gross Margin	87.93%	80.67%	90.39%	85.00%	88.29%	Upgrade
Operating Margin	-9.37%	-282.53%	-351.96%	-741.00%	-332.19%	Upgrade
Profit Margin	-14.57%	-283.64%	-339.74%	-767.00%	-321.46%	Upgrade
Free Cash Flow Margin	14.15%	-329.37%	-372.49%	-1127.00%	-386.83%	Upgrade
EBITDA	-56	-725	-771	-707	-650	Upgrade
EBITDA Margin	-5.83%	-269.52%	-	-	-	Upgrade
D&A For EBITDA	34	35	35	34	31	Upgrade
EBIT	-90	-760	-806	-741	-681	Upgrade
EBIT Margin	-9.37%	-282.53%	-	-	-	Upgrade

Source: S&P Global Market Intelligence. Standard template. Financial Sources.